文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

合生元补充对2型糖尿病患者肠道菌群、TNF-α及microRNA-126/146a表达的影响:双盲随机对照试验方案

Effects of synbiotic supplementation on gut microbiome, serum level of TNF-α, and expression of microRNA-126 and microRNA-146a in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomized clinical trial.
PubMed 文献 · Trials · 2020-04-14

主要观察肠道菌群、血清TNF-α水平及microRNA-126和microRNA-146a表达变化,并评估血糖血脂指标。该研究旨在探讨合生元通过调节菌群影响炎症及microRNA表达的潜力。

要点

  • 合生元干预12周,剂量1000 mg/日,安慰剂对照。
  • 主要结局包括肠道菌群、TNF-α及miR-126/146a表达。
  • 研究首次探讨合生元对T2DM患者菌群与相关microRNA的影响。

核心结论

  • 本试验将评估合生元对T2DM患者肠道菌群、血清TNF-α及microRNA-126/146a表达的影响。

研究设计与样本

  • 干预组每日1000 mg合生元(Familact),对照组安慰剂,持续12周。

关键数值与推荐

  • microRNA-126和microRNA-146a表达水平采用实时聚合酶链反应测定。
  • 血清TNF-α水平采用酶联免疫吸附试验试剂盒评估。
  • 肠道菌群采用定量聚合酶链反应方法在基线和试验结束时测定。
  • 血糖和血脂谱在基线和结束时进行生化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The dramatic increase in the prevalence of type 2 diabetes mellitus (T2DM) is a global major challenge to health. Circulating microRNAs have been suggested as promising biomarkers for different disorders such as diabetes. Imbalances in the gut microbiome have been revealed to contribute to the progression of multiple diseases including T2DM. Recently, the consumption of probiotics and synbiotics in the treatment of various diseases has shown a substantial growth. The anti-diabetes and anti-inflammatory effects of synbiotics have been indicated, which may be due to their beneficial effects on the gut microbiome. However, further research is needed to assess the effects of synbiotics on the microbiota and their impacts on expression of microRNAs relating to T2DM. Thus, we will aim to assess the effects of synbiotics on microbiota, serum level of tumor necrosis factor-α (TNF-α), and expression of microRNA-126 and microRNA-146a in patients with T2DM. METHODS: Seventy-two patients with T2DM will be recruited in this double-blind randomized parallel placebo-controlled clinical trial. After block matching based on age and sex, participants will be randomly assigned to receive 1000 mg/day synbiotic (Familact) or placebo for 12 weeks. The microRNA-126 and microRNA-146a expression levels will be measured by real-time polymerase chain reaction and serum TNF-α level will be assessed by enzyme-linked immunosorbent assay kit at the beginning and at the end of the study. Determination of the gut microbiota will be done by quantitative polymerase chain reaction methods at baseline and at the end of the trial. Biochemical assessments (glycemic and lipid profiles) will also be conducted at onset and end of the study. DISCUSSION: This is the first randomized controlled trial that will determine the effect of synbiotic supplementation on the gut microbiota and its probable impacts on serum levels of TNF-α and expression of related microRNAs in patients with T2DM. TRIAL REGISTRATION: Iranian Registry of Clinical Trials: IRCT20180624040228N2. Registered on 27 March 2019. http://www.irct.ir/trial/38371.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zeinali F, Aghaei Zarch SM, Vahidi Mehrjardi MY, et al. Effects of synbiotic supplementation on gut microbiome, serum level of TNF-α, and expression of microRNA-126 and microRNA-146a in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomized clinical trial. Trials. 2020. PMID: 32290852. doi:10.1186/s13063-020-04236-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。